{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-005777","form_type":"8-K","ticker":"CLDI","cik":"0001855485","company_name":"Calidi Biotherapeutics, Inc.","filed_at":"2025-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.190057+00:00","generated_at":"2026-05-23T08:23:21.581415+00:00","sec_items":["1.01","5.02","7.01","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Calidi appoints Eric Poma as CEO; Allan Camaisa resigns, remains director","bullets":["Allan Camaisa resigned as CEO and Chairman, effective April 21, 2025; will stay as Class III director and CEO Emeritus.","Eric Poma, Ph.D. named CEO and Class I director effective April 22, 2025; previously CEO of Molecular Templates (MTEM).","Poma receives $535k base salary, target bonus up to 50% of base, and option grant for 726,412 shares vesting over 4 years.","Camaisa gets $500k separation over 12 months, COBRA for 12 months, $10k/month transition pay, plus possible incentives through Dec 2026.","James Schoeneck appointed Chairman; board size increased from 5 to 6 members."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-005777","json":"https://secwatch.observer/filing/0001641172-25-005777.json","markdown":"https://secwatch.observer/filing/0001641172-25-005777.md","text":"https://secwatch.observer/filing/0001641172-25-005777.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225005777/0001641172-25-005777-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225005777/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T08:23:21.581415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1eef6f86fb","claim":"Eric Poma was appointed as Class I Director at Calidi Biotherapeutics, Inc..","evidence_excerpt":"the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dr. Poma to serve as a Class I director of the Company, also effective April 22, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225005777/0001641172-25-005777-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"5607762fa9","claim":"Allan Camaisa resigned as Chairman of the Board at Calidi Biotherapeutics, Inc..","evidence_excerpt":"Allan Camaisa notified the board of directors (“Board”) of Calidi Biotherapeutics, Inc. (the “Company”) of his resignation as the Company’s Chief Executive Officer (“CEO”) and as Chairman of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225005777/0001641172-25-005777-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"},{"claim_id":"7c1473c722","claim":"Eric Poma was appointed as Chief Executive Officer at Calidi Biotherapeutics, Inc..","evidence_excerpt":"the Board, by a unanimous vote, appointed Eric Poma, Ph.D. to serve as CEO of the Company, effective April 22, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225005777/0001641172-25-005777-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"e65b9cf399","claim":"Allan Camaisa resigned as Chief Executive Officer at Calidi Biotherapeutics, Inc..","evidence_excerpt":"Allan Camaisa notified the board of directors (“Board”) of Calidi Biotherapeutics, Inc. (the “Company”) of his resignation as the Company’s Chief Executive Officer (“CEO”) and as Chairman of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225005777/0001641172-25-005777-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}